218.52MMarket Cap-945P/E (TTM)
2.320High2.210Low313.90KVolume2.240Open2.220Pre Close711.66KTurnover0.41%Turnover RatioLossP/E (Static)96.69MShares6.04052wk High-1.27P/B174.22MFloat Cap0.94152wk Low--Dividend TTM77.09MShs Float56.590Historical High--Div YieldTTM4.96%Amplitude0.360Historical Low2.267Avg Price1Lot Size
ADC Therapeutics Stock Forum
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphomashowed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic respon...
NEWS
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
No comment yet